DDInter1451 DDInter1628
A drug that has anti-inflammatory, antipyretic, and analgesic activities. It is especially effective in the treatment of ankylosing spondylitis. It also is useful in rheumatoid arthritis and Reiter&#39;s syndrome (investigational indication). Although phenylbutazone is effective in gouty arthritis, risk/benefit considerations indicate that this drug should not be employed for this disease. (From AMA Drug Evaluations Annual, 1994, p1822)
Ruxolitinib, formerly known as INCB018424 or INC424, is an anticancer drug and a Janus kinase (JAK) inhibitor. It is a potent and selective inhibitor of JAK1 and JAK2, which are tyrosine kinases involved in cytokine signalling and hematopoiesis. Myeloproliferative neoplasms, such as myelofibrosis and polycythemia vera, are often characterized by aberrant activation of the JAK-STAT pathway, leading to abnormal blood cell counts and thrombotic complications. By inhibiting JAK1 and JAK2, ruxolitinib works to block the dysregulated cell signalling pathways and prevents abnormal blood cell proliferation. Due to a large number of patients with myeloproliferative neoplasms who have JAK2 mutations, ruxolitinib was the first ATP-competitive inhibitor of JAK1 and JAK2 ever developed. Ruxolitinib was first approved for the treatment of adult patients with myelofibrosis by the FDA in 2011, followed by EMA's approval in 2012. In 2014, it was approved for the treatment of polycythemia vera in adults who have an inadequate response to or are intolerant of [hydroxyurea] and in 2019, ruxolitinib was approved for use in steroid-refractory acute graft-versus-host disease in adults and children. The topical formulation of ruxolitinib is used to treat atopic dermatitis and vitiligo. It is being investigated for other inflammatory skin conditions. Ruxolitinib has been investigated to treat patients with coronavirus disease 2019 (COVID-19) accompanied by severe systemic hyperinflammation. In phase II clinical trials, ruxolitinib improved chest computed tomography and improved recovery in patients with lymphopenia.[A229713, A229718] However, phase III clinical trials later determined that ruxolitinib was inadequate in meeting its primary endpoint of reducing the number of hospitalized COVID-19 patients who experienced severe complications thus the drug was not approved as a treatment for COVID-19.
Phenylbutazone {u} (Compound) binds {v} (Gene) CYP3A4
CYP3A4 {u} (Gene) is bound by {v} (Compound) Ruxolitinib
Phenylbutazone {u} (Compound) binds {v} (Gene) PTGS2
PTGS2 {u} (Gene) is upregulated by {v} (Compound) Ruxolitinib
Phenylbutazone {u} (Compound) resembles {v} (Compound) Alverine
Alverine {u} (Compound) upregulates {v} (Gene) RRS1
RRS1 {u} (Gene) is upregulated by {v} (Compound) Ruxolitinib
Phenylbutazone {u} (Compound) binds {v} (Gene) PTGS2
PTGS2 {u} (Gene) is regulated by {v} (Gene) CAMK1D
CAMK1D {u} (Gene) is bound by {v} (Compound) Ruxolitinib
Phenylbutazone {u} (Compound) resembles {v} (Compound) Methadone
Methadone {u} (Compound) binds {v} (Gene) CYP3A4
CYP3A4 {u} (Gene) is bound by {v} (Compound) Ruxolitinib
Phenylbutazone {u} (Compound) binds {v} (Gene) PTGS2
PTGS2 {u} (Gene) is regulated by {v} (Gene) ZNF451
ZNF451 {u} (Gene) is upregulated by {v} (Compound) Ruxolitinib
Phenylbutazone {u} (Compound) resembles {v} (Compound) Fentanyl
Fentanyl {u} (Compound) binds {v} (Gene) CYP3A4
CYP3A4 {u} (Gene) is bound by {v} (Compound) Ruxolitinib
Phenylbutazone {u} (Compound) resembles {v} (Compound) Methadone
Methadone {u} (Compound) causes {v} (Side Effect) Headache
Headache {u} (Side Effect) is caused by {v} (Compound) Ruxolitinib
Phenylbutazone {u} (Compound) resembles {v} (Compound) Fentanyl
Fentanyl {u} (Compound) causes {v} (Side Effect) Anaemia
Anaemia {u} (Side Effect) is caused by {v} (Compound) Ruxolitinib
Phenylbutazone {u} (Compound) binds {v} (Gene) PTGS2
PTGS2 {u} (Gene) regulates {v} (Gene) C2CD2L
C2CD2L {u} (Gene) is upregulated by {v} (Compound) Ruxolitinib
Phenylbutazone (Compound) binds CYP3A4 (Gene) and CYP3A4 (Gene) is bound by Ruxolitinib (Compound)
Phenylbutazone (Compound) binds PTGS2 (Gene) and PTGS2 (Gene) is upregulated by Ruxolitinib (Compound)
Phenylbutazone (Compound) resembles Alverine (Compound) and Alverine (Compound) upregulates RRS1 (Gene) and RRS1 (Gene) is upregulated by Ruxolitinib (Compound)
Phenylbutazone (Compound) binds PTGS2 (Gene) and PTGS2 (Gene) is regulated by CAMK1D (Gene) and CAMK1D (Gene) is bound by Ruxolitinib (Compound)
Phenylbutazone (Compound) resembles Methadone (Compound) and Methadone (Compound) binds CYP3A4 (Gene) and CYP3A4 (Gene) is bound by Ruxolitinib (Compound)
Phenylbutazone (Compound) binds PTGS2 (Gene) and PTGS2 (Gene) is regulated by ZNF451 (Gene) and ZNF451 (Gene) is upregulated by Ruxolitinib (Compound)
Phenylbutazone (Compound) resembles Fentanyl (Compound) and Fentanyl (Compound) binds CYP3A4 (Gene) and CYP3A4 (Gene) is bound by Ruxolitinib (Compound)
Phenylbutazone (Compound) resembles Methadone (Compound) and Methadone (Compound) causes Headache (Side Effect) and Headache (Side Effect) is caused by Ruxolitinib (Compound)
Phenylbutazone (Compound) resembles Fentanyl (Compound) and Fentanyl (Compound) causes Anaemia (Side Effect) and Anaemia (Side Effect) is caused by Ruxolitinib (Compound)
Phenylbutazone (Compound) binds PTGS2 (Gene) and PTGS2 (Gene) regulates C2CD2L (Gene) and C2CD2L (Gene) is upregulated by Ruxolitinib (Compound)